CAP/HAP/LRTI/URTI Flashcards
CAP Main Causative Agent
S. Pneumoniae
Main difference between In/Outpatient CAP
Inpatient caused by more atypical agents
Typical Characteristics
OCCUR W/IN 24 HR (abrupt onset): fever/chills/sweats, purulent sputum production, unilateral well-defined infiltrate, cough, general predominance of pleuritic chest pain (primarily pulmonary sx)
Atypical Characteristics
Gradual Onset: diffuse infiltrates (ground-glass appearance), mild fever/dyspnea, dry cough, myalgias,/diarrhea/abdominal pain (extrapulmonary sx common)
CAP: S. Pneumoniae RF
Rusty colored sputum (SEVERE, maybe mild/mod)
CAP: H. Influenzae, M. Catarrhalis RF
COPD, EtOH abuse, CF, HIV, Impaired Humoral Immunity
CAP: Anaerobes RF
Loss of consciousness after EtOH/drug overdose, post seizure, gingival disease, esophageal motility disorder
CAP: CA-MRSA RF
RARE; After influenza, cavity lesions, Severe CAP/ICU admission, empyema
CAP: Legionella pneumophilia
Occurs after water exposure/more in males/smokers; presents w/ severe hypophosphatemia, hyponatremia, diarrhea, confusion, HA, Bradycardia, LFT elevations, pulse-temperature dissociation; ABX include FQ (IV LEVO 10-21d), Azithromycin
CAP Outpatient Treatment
PO AMOXICILLIN (Doxycycline if Blactam allergy, Macrolide) Comorb: PO Augmentin or Cephalosporin (cefpodox, cefdinir, cefurox) + Macrolide (azithro, clarithro) *PO FQ (levo, moxi)
CAP Comorbidities
Age <2 or >65, Blactam w/in 3 mo prior, EtOH abuse, Immunosuppression, exposure to daycare, cancer, chronic respiratory disease
CAP Inpatient Treatment
Non-severe/Severe: IV Blactam (amp/sul, CEFTRIAXONE) + Macrolide/FQ
*de-escalate asap
Severe CAP defined as…
SEPSIS
CAP ABX Duration
5-7d (for severe may go longer), should be afebrile for 48-72 hrs
CAP Pretreatment Tests
Blood cultures and Sputum samples for all w/ anti-MRSA/Pseudomonal abx orders
Urinary Antigen Test for Legionella and S. pneumoniae for those w/ Severe CAP
Switch from IV to PO…
when hemodynamically stable, clinical improvement, can tolerate PO, normal functioning GI
Viral Pneumonia (non-covid)
More common in kids, signif morbidity in elderly, can result in co-infection w/ bacteria
CAP Main Causative Agent
+:S. Aureus (MRSA)
-: K. Pneumoniae, P. Aeruginosa
Empiric Therapy for HAP/VAP?
Broad: late onset (>5d) of MDR RF (prior abx, colonization, hospitalization, chronic care, immunosuppressive disease/therapy)
*limited otherwise
HAP/VAP Empiric Therapy
Ceftriaxone -> Amp/Sul (reserve levo/moxi, ertapenem for Blactam allergy)
HAP/VAP Empiric MRSA Coverage…
when: prior IV abx use w/in prev 90d, >20% MRSA in area, severe presentation (septic shock, vent. support), prev inf)
how: Vancomycin, Linezolid
HAP/VAP Empiric Pseudomonas Coverage…
when: prior IV abx use w/in prev 90d, severe presentation (septic shock, vent. support), prev inf), immunosuppression
how: CEFEPIME, Pip/Tazo (renaltox)
* Ceftazidime, Imipenem. Meropenem, Aztreonam, FQ (cip/levo), aminoglycosides, Colistin/PolyB reserved
HAP/VAP Cultures
1st obtain cultures noninvasively (endotracheal aspiration) and then BAL if possible
HAP/VAP ABX Duration
7d